Cellular & Inflammatory Pathways in Ashtma & Allergic Diseases: From IgE to Cells

蜂窝网络

• 批准号: 8243656
• 负责人: Lawrence B. Schwartz
• 金额: $ 142.69万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8243656
• 关键词: 2,4-Dinitrophenol; Affect; Allergens; Allergic Disease; Allergic inflammation; Anaphylaxis; Antigens; Asthma; Attenuated; B-Lymphocytes; Basophils; Bone Marrow; Cell physiology; Cells; Characteristics; Clinical; Clinical Markers; Clinical Research; Collaborations; Complex; Data; Dendritic Cells; Development; Disease; Disease Progression; Dose; Effectiveness; Effector Cell; Elements; Environmental Risk Factor; Extrinsic asthma; Faculty; Future; Genetic; Goals; Growth; Health; Helper-Inducer T-Lymphocyte; Heterophile Antigens; Hour; House Dust; Human; Hypersensitivity; IgE; Immediate hypersensitivity; Immune; Immune system; Immunotherapy; In Vitro; Individual; Inflammatory; Inflammatory Infiltrate; Interleukin-13; Interleukin-3; Interleukin-4; Interleukin-5; Interleukin-9; Investigation; Lead; Learning; Lung; Lymphocyte; Mediating; Mediator of activation protein; Modeling; Molecular; Molecular Biology; Mucous body substance; Mus; Pathogenesis; Pathway interactions; Patients; Penicillins; Peptide Hydrolases; Pharmaceutical Preparations; Phenotype; Phosphorylation Site; Phosphotransferases; Physicians; Play; Process; Production; Protein Kinase C; Protein Tyrosine Kinase; Protocols documentation; Reagent; Regulation; Regulatory T-Lymphocyte; Research; Research Personnel; Research Project Grants; Risk; Role; SPHK1 enzyme; Secretory Vesicles; Serum; Signal Transduction; Signaling Molecule; Skin; Small Interfering RNA; Surface; System; Testing; Th2 Cells; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Translating; Tryptase; Universities; Ursidae Family; Virginia; Work; airway hyperresponsiveness; airway inflammation; allergic airway disease; allergic airway inflammation; allergic response; anti-IgE; antigen desensitization; asthmatic airway; base; body system; ceramide 1-phosphate; ceramide kinase; cytokine; desensitization; disorder risk; eosinophil; extracellular; human SYK protein; human subject; human tissue; improved; in vivo; inhibitor/antagonist; insight; kinase inhibitor; lipid mediator; mast cell; novel; novel therapeutic intervention; peripheral blood; prevent; programs; receptor; response; sphingosine 1-phosphate; sphingosine kinase; src-Family Kinases; ubiquitin-protein ligase

DESCRIPTION (provided by applicant): Asthma and allergic diseases are multifactorial, complex diseases involving the innate and adaptive immune systems as well as environmental factors. Allergic asthma is characterized by airway hyperreactivity (AHR), inflammatory infiltrates containing eosinophilic leukocytes, lymphocytes, and mast cells, increased mucus secretion, and elevated serum IgE levels. Type 2 helper T lymphocytes (Th2) play a critical role in orchestrating allergic airway inflammation. Upon recognition of their cognate antigen, Th2 cells produce cytokines that regulate IgE synthesis (IL-4 and IL-13), and growth and activation of eosinophils (IL-5) and mast cells (IL-3 and IL-4). IL-13 and IL-9 control mucus production and AHR. Allergen-induced airway inflammation can be triggered by NKT cells and is antagonized by regulatory T (Treg) cells. Despite these progresses in our understanding of allergy pathogenesis and improved therapeutics, there remains a great deal to be learned to better control asthma and other allergic diseases. To attack these complex diseases, our approaches in investigation need to be multi-faceted. In this group project, we will investigate how allergic inflammation orchestrated by Th2 cells is regulated at cellular and molecular levels. To fulfill this common goal, we will study innate immune (dendritic cell and NKT cell) responses to an environmental factor, house dust extracts (HDEs), in Project 1. We will study how Th2 cells are regulated by protein kinase C? (PKC?) in Project 2, how different IgEs differentially affect mast cell activation in Project 3, and how Treg cells are regulated by Itch, an E3 ubiquitin ligase, in Project 4. Therefore, we will study the pathogenetic roles of the cells that belong to the innate and adaptive immune systems. The molecules we characterize with regard to allergy pathogenesis are widely varied, encompassing an environmental factor (HDEs), a secreted molecule (IgE), and intracellular signaling molecules (PKC9 and Itch). As described above, these cellular and molecular elements all likely contribute to various aspects of the pathogenesis of allergic asthma and other allergic diseases. Each component in this group can stand alone as an individual research project deals with an important, unique aspect of allergic diseases. However, cooperation among individual components will be multi-layered, e.g., exchanges of ideas, sharing reagents, protocols, and data, and formal and informal collaborations, to achieve our common goal of better understanding the diseases, just as allergic diseases involve various layers of extracellular, cellular, and intracellular elements. Upon completion of the program project, we will have gained a novel, unique, integrated set of insights into allergic diseases at all these layers. PROJECT 1: Desensitization of human mast cells: mechanisms and potential utility of attenuating asthma and allergic disease (Schwartz, L) PROJECT 1 DESCRIPTION (provided by applicant): Asthma and allergic diseases are important health concerns, and mast cells and possibly basophils are the major effector cells of IgE-mediated immediate hypersensitivity in humans. Previous work by the investigators involved in Project 1 includes developing tryptase as a clinical marker for mast cell activation; finding activation of mast cells in the asthmatic airway and during systemic anaphylaxis; identifying two types of human mast cells (MCT and MCTC) based on the protease content of their secretory granules and the surface expression of CD88; discovering the activating form of FcyRII, CD32a, constitutively expressed on the surface of skin MCTC cells; and finding Syk-deficiency in basophils with the non-releaser phenotype and in mast cells after antigen desensitization in vitro. The three specific aims of the current project are to: 1. Test the hypothesis that human mast cells and basophils in vitro undergo cross-desensitization to different antigens and heterologous desensitization through FcyRI and FcyRlla. Indeed, preliminary data suggest that when mast cells of the MCTC type are IgE anti-DNP-sensitized and then desensitized with low doses of DNP-BSA, both cross-desensitization and heterologous desensitization occurs. 2. Explore in vitro the mechanism(s) for desensitization of human mast cells involving Src and/or Syk tyrosine kinases. Although Syk depletion seems likely, the involvement of Lyn and/or Fyn is uncertain. Further, the possibility that subcellular compartmentalization of signaling differs for desensitization and activation will be examined. Collaborations with Project 3 on studies of Lyn kinase involvement in desensitization, and with Project 4 on the involvement of sphingosine kinase-1 in desensitization of human mast cells and basophils facilitate these mechanistic studies. 3. Determine whether penicillin desensitization of human subjects in vivo produces antigen cross-desensitization of mast cells and basophils and depletes Syk from peripheral blood basophils. This clinical study will begin to translate our in vitro findings to the in vivo situation. Clinical tolerance due to desensitization can be distinguished from that due to immunotherapy by its rapid induction (hours) and short persistence (days) once allergen administration ceases. We hypothesize that desensitization targets primarily mast cells and basophils. Understanding more precisely the characteristics of and the mechanism(s) behind desensitization will enable physicians to better utilize this approach to reduce mast cell/basophil-mediated contributions to asthma and allergic diseases.

描述（由申请人提供）：哮喘和过敏性疾病是涉及先天性和适应性免疫系统以及环境因素的多因素复杂疾病。过敏性哮喘的特征在于气道高反应性（AHR），含有嗜酸性白细胞、淋巴细胞和肥大细胞的炎性浸润，粘液分泌增加和血清IgE水平升高。2型辅助性T淋巴细胞（Th 2）在协调过敏性气道炎症中发挥关键作用。在识别其同源抗原后，Th 2细胞产生调节IgE合成（IL-4和IL-13）以及嗜酸性粒细胞（IL-5）和肥大细胞（IL-3和IL-4）的生长和活化的细胞因子。IL-13和IL-9控制粘液产生和AHR。过敏原诱导的气道炎症可由NKT细胞触发，并被调节性T（Treg）细胞拮抗。尽管我们对变态反应发病机制的理解和治疗方法的改进取得了这些进展，但要更好地控制哮喘和其他变态反应性疾病，仍有很多东西需要学习。为了对付这些复杂的疾病，我们的调查方法需要是多方面的。在这个小组项目中，我们将研究如何由Th 2细胞编排的过敏性炎症在细胞和分子水平上进行调节。为了实现这一共同目标，我们将在项目1中研究先天免疫（树突状细胞和NKT细胞）对环境因素（屋尘提取物（HDES））的反应。我们将研究如何调节Th 2细胞的蛋白激酶C？(PKC?)在项目2中，在项目3中，不同的IgE如何不同地影响肥大细胞活化，以及在项目4中，Treg细胞如何被Itch（一种E3泛素连接酶）调节。因此，我们将研究属于先天性和适应性免疫系统的细胞的致病作用。我们描述的过敏发病机制的分子是多种多样的，包括环境因素（HDE），分泌的分子（IgE），和细胞内信号分子（PKC 9和瘙痒）。如上所述，这些细胞和分子元素都可能有助于过敏性哮喘和其他过敏性疾病的发病机制的各个方面。这一组中的每个组成部分都可以独立作为一个单独的研究项目，处理过敏性疾病的一个重要的，独特的方面。然而，各个组件之间的合作将是多层次的，例如，交流思想，共享试剂，协议和数据，以及正式和非正式的合作，以实现我们更好地了解疾病的共同目标，就像过敏性疾病涉及细胞外，细胞内和细胞内元素的各个层面一样。在项目完成后，我们将在所有这些层面上获得一套新颖，独特，综合的过敏性疾病见解。 项目1：人肥大细胞的脱敏：减轻哮喘和过敏性疾病的机制和潜在效用（Schwartz，L） 项目1描述（由申请人提供）：哮喘和过敏性疾病是重要的健康问题，肥大细胞和可能的嗜碱性粒细胞是人体IgE介导的速发型超敏反应的主要效应细胞。参与项目1的研究人员先前的工作包括开发类胰蛋白酶作为肥大细胞活化的临床标志物;发现哮喘气道和全身过敏反应期间肥大细胞的活化;鉴定两种类型的人类肥大细胞。（MCT和MCTC），基于其分泌颗粒的蛋白酶含量和CD 88的表面表达;发现Fc γ RII的活化形式，CD 32a，在皮肤MCTC细胞的表面上组成性表达;以及在体外抗原脱敏后，在具有非荧光素酶表型的嗜碱性粒细胞和肥大细胞中发现Syk缺陷。本项目的三个具体目标是：1.测试人肥大细胞和嗜碱性粒细胞在体外经历对不同抗原的交叉脱敏和通过Fc γ RI和Fc γ RIIa的异源脱敏的假设。事实上，初步数据表明，当MCTC型肥大细胞是IgE抗DNP致敏的，然后用低剂量的DNP-BSA脱敏时，发生交叉脱敏和异源脱敏。2.体外探索Src和/或Syk酪氨酸激酶对人肥大细胞脱敏的机制。虽然Syk耗尽似乎是可能的，但林恩和/或Fyn的参与是不确定的。此外，亚细胞区室化的信号转导不同的脱敏和激活的可能性将被检查。与项目3合作研究林恩激酶参与脱敏，与项目4合作研究鞘氨醇激酶-1参与人类肥大细胞和嗜碱性粒细胞脱敏，促进了这些机制研究。3.确定人类受试者体内青霉素脱敏是否产生肥大细胞和嗜碱性粒细胞的抗原交叉脱敏，并从外周血嗜碱性粒细胞中清除Syk。这项临床研究将开始将我们的体外发现转化为体内情况。脱敏引起的临床耐受性与免疫治疗引起的临床耐受性的区别在于，一旦过敏原给药停止，脱敏引起的临床耐受性可快速诱导（数小时）和短暂持续（数天）。我们假设脱敏作用主要针对肥大细胞和嗜碱性粒细胞。更准确地理解脱敏的特征和机制将使医生能够更好地利用这种方法来减少肥大细胞/嗜碱性粒细胞介导的哮喘和过敏性疾病的贡献。

项目成果

Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity.

• DOI: 10.4049/jimmunol.1200647
• 发表时间: 2012-07-15
• 期刊: Journal of immunology (Baltimore, Md. : 1950)
• 作者: Saleem SJ;Martin RK;Morales JK;Sturgill JL;Gibb DR;Graham L;Bear HD;Manjili MH;Ryan JJ;Conrad DH
• 通讯作者: Conrad DH

Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells.

细胞内腺苷抑制人类皮肤肥大细胞的IgE依赖性脱粒。

• DOI: 10.1007/s10875-013-9950-x
• 发表时间: 2013-11
• 期刊: Journal of clinical immunology
• 影响因子: 9.1
• 作者: Gomez G;Nardone V;Lotfi-Emran S;Zhao W;Schwartz LB
• 通讯作者: Schwartz LB

Total tryptase levels indicate risk for systemic reactions to rush immunotherapy and mast cell activation.

总类胰蛋白酶水平表明急速免疫治疗和肥大细胞激活存在全身反应的风险。

• DOI: 10.1016/j.anai.2010.12.015
• 发表时间: 2011
• 期刊: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
• 作者: Vegh,ArthurB;George,KimberlyC;Lotfi-Emran,Sahar;Butler,NicoletteE;Schwartz,LawrenceB
• 通讯作者: Schwartz,LawrenceB

Mast cell regulation of the immune response.

• DOI: 10.1097/wox.0b013e3181c2a95e
• 发表时间: 2009-10
• 期刊: The World Allergy Organization journal
• 作者: Ryan JJ;Morales JK;Falanga YT;Fernando JF;Macey MR
• 通讯作者: Macey MR